Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 19/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | BID | P55957 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.77 |
| ▸ | ASPH | Q12797 | 1/20 | 0.77 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.77 |
| ▸ | BAD | Q92934 | 1/20 | 0.77 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.77 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837102 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL29946242 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL29384973 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL20580494 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL20580574 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL29376496 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL29374246 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL19839481 | 0.97 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL19839476 | 0.97 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL29376685 | 0.97 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281511-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-09-11 | — | — | US | claimed |
| US-20250099440-A1 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| EP-4382126-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2024-06-12 | — | — | EP | claimed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | claimed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| US-20220323465-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-13 | — | — | US | claimed |
| US-20220305034-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-29 | — | — | US | claimed |
| US-20210275522-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2021-09-09 | — | — | US | claimed |
| US-12514863-B2 | Pharmaceutical combination and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-01-06 | — | — | US | disclosed |
| US-20250333415-A1 | CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYL SULFONYL) BENZAMIDE COMPOUNDS OR ITS SALTS OR SOLVATES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-10-30 | — | — | US | disclosed |
| US-20250281511-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-12358912-B2 | Crystalline forms or amorphous forms of N-(phenyl sulfonyl) benzamide compounds or its salts or solvates | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| US-12343352-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-01 | — | — | US | disclosed |
| EP-3569601-A2 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL3, BCL6 | BCL2 8/4885NSD2 2490/4885ADORA3 4567/4885 |
| US-20250099440-A1 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | MCL1, TP53, BCL2 | BCL2 3/4885NSD2 925/4885ADORA3 3468/4885 |
| US-12358912-B2 | Crystalline forms or amorphous forms of N-(phenyl sulfonyl) benzamide compounds or its salts or solvates | BCL2, BCL2L2, BCL3 | BCL2 1/4885NSD2 164/4885ADORA3 4676/4885 |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | BCL2 43/4885NSD2 3464/4885ADORA3 4530/4885 |
| US-20210275522-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | CDK2, CDK5, CDK6 | BCL2 4/4885NSD2 497/4885ADORA3 4635/4885 |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885NSD2 214/4885ADORA3 2822/4885 |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | BCL2 3/4885NSD2 214/4885ADORA3 2822/4885 |
| US-20250281511-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL3, BCL2, MCL1 | BCL2 2/4885NSD2 32/4885ADORA3 4828/4885 |
| US-20220305034-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL3, BCL2, MCL1 | BCL2 2/4885NSD2 32/4885ADORA3 4828/4885 |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | BCL2, BCL3, BCL2L13 | BCL2 1/4885NSD2 1605/4885ADORA3 3659/4885 |
| US-20220323465-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | MCL1, BCL2, BAK1 | BCL2 2/4885NSD2 292/4885ADORA3 4025/4885 |
| US-12343352-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL3, BCL2, MCL1 | BCL2 2/4885NSD2 32/4885ADORA3 4828/4885 |
| US-20250333415-A1 | CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYL SULFONYL) BENZAMIDE COMPOUNDS OR ITS SALTS OR SOLVATES | BCL2, BCL2L2, BCL3 | BCL2 1/4885NSD2 164/4885ADORA3 4676/4885 |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | BCL2 3/4885NSD2 202/4885ADORA3 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.